GE

Genexine, Inc.

Clinical-stage biotech developing long-acting therapeutics for oncology and rare diseases.

095700 | KO

Overview

Corporate Details

ISIN(s):
KR7095700001
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙로 172 바이오이노베이션파크, 강서구

Description

Genexine, Inc. is a clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation biologics. The company utilizes its proprietary hyFc® platform technology to create long-acting protein therapeutics. Its pipeline is led by GX-I7, a long-acting interleukin-7 designed to amplify T-cell counts for immuno-oncology applications. Other key assets in late-stage clinical trials include GX-E4, a long-acting treatment for anemia, and GX-H9 for growth hormone deficiency. Genexine's research and development efforts primarily target oncology and rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-11-15 00:00
[기재정정]증권신고서(지분증권) (2022.12)
Korean 3.2 MB
2022-11-15 00:00
[기재정정]투자설명서
Korean 3.2 MB
2022-11-14 00:00
분기보고서 (2022.09)
Korean 1.7 MB
2022-11-10 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.2 KB
2022-11-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.0 KB
2022-11-08 00:00
[발행조건확정]증권신고서(지분증권)
Korean 175.0 KB
2022-11-08 00:00
[기재정정]투자설명서
Korean 2.6 MB
2022-11-08 00:00
유상증자1차발행가액결정
Korean 7.9 KB
2022-11-08 00:00
[기재정정]주요사항보고서(유무상증자결정)
Korean 43.8 KB
2022-11-08 00:00
권리락(유상증자)
Korean 3.5 KB
2022-11-07 00:00
투자설명서
Korean 2.5 MB
2022-10-21 00:00
[기재정정]증권신고서(지분증권) (2022.12)
Korean 3.4 MB
2022-10-20 00:00
[기재정정]주요사항보고서(유무상증자결정)
Korean 59.2 KB
2022-09-27 00:00
증권신고서(지분증권) (2022.11)
Korean 2.3 MB
2022-09-26 00:00
주권매매거래정지(무상증자)
Korean 4.7 KB

Automate Your Workflow. Get a real-time feed of all Genexine, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genexine, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genexine, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.